Gilead’s selonsertib fails in PhIII NASH trial
Gilead’s selonsertib has failed to hit a key target in a late-stage study involving patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH).
Read More
Tag: selonsertib
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
